OPENING SESSION

FIRST SESSION: A GLOBAL VIEW OF SELF-CARE WITHIN HEALTH POLICY

A blueprint for responsible self-medication - Guiding Principles in Self-Medication
Mr Anthony Jamison, Chairman, World Self-Medication Industry (WSMI) and President, Roche Consumer Health Worldwide

WHO health policy and self-care
Dr Gro Harlem Brundtland, Director-General, World Health Organization

The need for self-medication: an opportunity for the pharmaceutical industry
Dr Martin Bangemann, European Commissioner for Industrial Policy and Telecommunication

What self-care means to medical doctors
Dr Anders Milton, Chairman, Council of the World Medical Association (WMA)

SECOND SESSION: SOCIAL AND ECONOMIC VALUE - TWO SIDES OF THE SELF-MEDICATION COIN

Responsible self-medication:a challenge to consumers and industry
Nadine Gasman MD, DrPh, International Public Health Consultant, Mexico

How consumer education enhances the economic value of self-medication - Is there any substitution between medical services and over-the-counter medication in the case of the common cold?
Professor Masako Ii, Yokohama National University, Japan

The socio-economic importance of self-medication
Dr Frank Morich, President, Bayer Consumer Care

Conclusions of the session
Mr Jean-François Bénard, Past President, Commission Économique du Médicament, France

THIRD SESSION: EXPANDING THE BOUNDARIES OF SELF-MEDICATION IN A GLOBAL CONTEXT

Chairman's introduction
Mr Fernand Sauer, Executive Director, European Agency for the Evaluation of Medicinal Products (EMEA)

Creating a global brand
Mr Tom Blinn, Vice President, Global Personal Healthcare, Procter & Gamble

Changing legal status and distribution channels
Mr Seiichi Sato, President, Sato Pharmaceuticals Co and Vice-Chairperson, Proprietary Association of Japan (PAJ)

Self-medication and the global needs of healthcare consumers: thinking outside the box
Mr Jack Ziegler, President, SmithKline Beecham Consumer Healthcare

Rx-to-OTC switch: a global perspective
Dr Bernd Eberwein, Director, Bundesfachverband der Arzneimittel-Hersteller (BAH), Germany

The internationalisation of herbal medicinal products
Dr Konstantin Keller, Chairman, Working group on herbal medicinal products, European Agency for the Evaluation of Medicinal Products (EMEA)

Consumers: ignore them at your peril
Ms Janne Graham, Visiting Fellow, Australian National University, National Centre for Epidemiology and Health; Former Chairperson, Consumers' Health Forum of Australia

FOURTH SESSION: PANEL DISCUSSION

Information age healthcare and the informed consumer

Panellists:

• Ms Janne Graham, Visiting Fellow, Australian National University, National Centre for Epidemiology and Population Health and former Chairperson, Consumers' Health Forum of Australia
• Mr Patrick Deboyser, Head of Unit, Pharmaceuticals and Cosmetics, European Commission and Members of the ICH Steering Committee
• Mr Peter Kielgast, President, International Pharmaceutical Federation (FIP), The Hague.
• Dr Delon Human, Secretary General, World Medical Association (WMA); Geneva
• Mr Edgardo Gezzi, Vice-Chairman for Latin America, WSMI, Secretary General, Latin-American OTC Association (ALPO) and Managing Partner, Laboratories E J Gezzi, Argentina
• Mr Jean-François Bénard, Past President, Comité Economique du Médicament, France
• Mr Fumio Kita, Director, SS Pharmaceutical Co and Chairperson, Drug Information Committee, Proprietary Association of Japan (PAJ)
• Mr Luk Herten, President, OTC Section, Association Générale du Médicament (AGIM), Belgium

CLOSING SESSION: CONCLUDING PERSPECTIVES ON SELF-CARE IN HEALTH POLICY

Regulatory policy and self-care in the United States
Murray M. Lumpkin, M.D., Deputy Center Director, Center for Drug Evaluation and Research, Food and Drug Administration (FDA), United States

Invitation to the 36th AESGP Annual Meeting in Helsinki, Finland, 17-20 May 2000
Mr Jarmo Lehtonen, Managing Director, Pharma Industry Finland (PIF)

Constructing the future
Mr Akira Uehara, Incoming Chairman, World Self-Medication Industry (WSMI) and President, Taisho Pharmaceutical Company, Japan

Closing remarks
Dr Gerhard Stummerer, President, Association of the European Self-Medication Industry (AESGP)

WORKSHOP: EFFECTIVE RX-TO-OTC SWITCHING

Introduction
Dr Jerome A Reinstein, Director General, World Self-Medication Industry (WSMI)
Introduction
Prof. Dr Alfred Hildebrandt, Director, Institute for Medicinal Products and Medical Devices (BfArM), Germany

Basis for switching
Dr Hubertus Cranz, Director General, Association of the European Self-Medication Industry (AESGP) Vice President for Europe and Africa, World Self-Medication Industry (WSMI)

Successful Rx-to-OTC switches
Mr William Quaeyhaegens, Vice-President SelfMedication, IMS Health, Brussels

Switching around the world: Germany
Dr Mark Seidscheck, Director-General, Bundesfachverband der Arzneimittel-Hersteller (BAH), Germany

Switching around the world: France
Mr Hugues Lanrezac / Mme Catherine Pouletty, Association Française de l'Industrie Pharmaceutique pour une Automédication Responsable (A.F.I.P.A), France

Switching around the world: Spain
Mr Rafael García Gutiérrez, Asociación Nacional de Especialidades Farmacéuticas Publicitarias (ANEFP), Spain

Switching around the world: United Kingdom
Ms Sheila Kelly, Proprietary Association of Great Britain (PAGB), United Kingdom

Switching around the world: United States
Mr David Spangler, Consumer Healthcare Products Association (CHPA), USA

Switching around the world: Mexico
Mr Héctor Bolaños, Asociación de Fabricantes de Medicamentos de Libre Acceso, A.C. (AFAMELA), Mexico

Switching around the world: Japan
Mr Keigo Danjoh / Mr Hiroshi Kumagai, Proprietary Association of Japan (PAJ)

Switching around the world: Australia
Ms Juliet Seifert, Proprietary Medicines Association of Australia

Benefit/risk decision-making as the final common pathway to OTCness
R. William Soller PhD, Senior Vice President and Director of Science and Technology, Consumer Healthcare Products Association (CHPA), United States

REGULATORS' FORUM: GUIDING PRINCIPLES ON SELF-MEDICATION

• Dr Jerome A Reinstein, Director General, World Self-Medication Industry (WSMI)
• Prof. Dr Alfred Hildebrandt, Director, Institute for Medicinal Products and Medical Devices (BfArM), Germany

Panellists:

• Mr Alfred Jost, Deputy Director, Swiss Regulatory Authority
• Dr June Raine, Medicines Control Agency (MCA), United Kingdom
• Prof. Le Van Truyen, Vice-Minister of Health, Vietnam
• Professor Lembit Rägo, Director General, State Agency of Medicines, Estonia
• Dr Milan Šmíd, Director, State Institute for Drug Control, Czech Republic
• Mr José Campillo, Under Secretary of Health, Mexico
• Mr Tom McGuinn, Chief Pharmacist, Ministry of Health, Ireland
• Professor Jasmina Mircheva, Director for Medicinal Affairs and Central & Eastern Europe, AESGP
• Dr Bernd Eberwein, Director, Bundesfachverband der Arzneimittel-Hersteller (BAH), Germany.
• Mrs Geeta Lingam, Head of International OTC Regulatory Affairs, Glaxo Wellcome, United Kingdom
• Mr Ralf Müller, Director for Strategic Projects, AESGP
• Dr Flavio Vormittag, Medical Director, Whitehall and Medical Director, Self-medication Industry As-sociation, Brazil
• Dr Gonzalo Vecina Neto, Head, National Regulatory Agency, Brazil
• Mr Victor Dimitriev, Deputy Director, Research Centre for Drugs Evaluation and State Control, Rus-sian Federation
• Mrs Elena Barmanova, Research Centre for Drugs Evaluation and State Control, Russian Federation
• Mrs Elena Volskaya, Research Centre for Drugs Evaluation and State Control, Russian Federation.
• Professor Alexander Rudakov, Director, National Institute for Preclinical and Clinical Drug Evalua-tion, Russian Federation
• Professor Vladas Volbekas, Chairman, Drug Registration Commission, State Medicines Control Agency, Lithuania
• Professor L'udevit Martinec, Director, State Institute for the Control of Drugs, Slovak Republic
• Professor Aleksander Mazurek, Director, Drug Institute and Chairman, Drug Registration Committee, Poland
• Mr Tomasz Krasucki, Chairman, Bureau of Registration of Drugs and Medical Devices, Drug Institute, Poland
• Professor Tamás Paál, Director-General, National institute of Pharmacy, Hungary and Head, Department of Pharmacy, "Haynal Imre" University of Health Sciences, Budapest
• Dr Gonzalo Navarrete, Director, Institute of Public Health, Chile
• Mr Graham Peachey, Therapeutic Goods Administration (TGA), Australia
• Professor Alfred Hildebrandt, Director, Institute for Medicines and Medical Devices (BfArM), Germany
• Dr Murray Lumpkin, Deputy Center Director (Review Management), Center for Drug Evaluation & Research, Food and Drug Administration (FDA), United States.